Lexeo Therapeutics, Inc. Common Stock (LXEO) vs Palisade Bio, Inc. (PALI)
A side-by-side comparison of Lexeo Therapeutics, Inc. Common Stock and Palisade Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LXEO
Lexeo Therapeutics, Inc. Common Stock
$3.29HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
PALI
Palisade Bio, Inc.
$1.51HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — LXEO vs PALI
growth of $100 · dividends reinvested · last 3yLXEO -66.1% (-30.3%/yr)PALI -83.2% (-44.9%/yr)LXEO compounded faster over this window
LXEO PALI
LXEO vs PALI: by the numbers
- •PALI is the larger company ($262M vs $258M market cap).
- •Both run net losses; LXEO's is the smaller (0.00% vs -6388.20% net margin).
Metrics side by side
Valuation
| Metric | LXEO | PALI |
|---|---|---|
| P/S ratio | N/A | 524.21 |
| P/B ratio | 1.10 | 2.15 |
Profitability
| Metric | LXEO | PALI |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | -6388.20% |
| ROE | -37.12% | -26.24% |
| ROIC | -39.76% | -28.96% |
Growth (annualized)
| Metric | LXEO | PALI |
|---|---|---|
| Total return CAGR (5Y) | N/A | -76.02% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.